Journal
UPSALA JOURNAL OF MEDICAL SCIENCES
Volume 124, Issue 4, Pages 218-227Publisher
UPSALA MED SOC
DOI: 10.1080/03009734.2019.1688433
Keywords
Bacteriophage; phage therapy; pharmacodynamics; pharmacokinetics; pharmacology
Categories
Funding
- Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning (FORMAS) [221-2015-1894]
- Olle Engkvist Byggmastare Foundation [2015/419]
Ask authors/readers for more resources
Clinical trial results of phage treatment of bacterial infections show a low to moderate efficacy, and the variation in infection clearance between subjects within studies is often large. Phage therapy is complicated and introduces many additional components of variance as compared to antibiotic treatment. A large part of the variation is due to in vivo pharmacokinetics and pharmacodynamics being virtually unknown, but also to a lack of standardisation. This is a consequence of the great variation of phages, bacteria, and infections, which results in different experiments or trials being impossible to compare, and difficulties in estimating important parameter values in a quantitative and reproducible way. The limitations of phage therapy will have to be recognised and future research focussed on optimising infection clearance rates by e.g. selecting phages, bacteria, and target bacterial infections where the prospects of high efficacy can be anticipated, and by combining information from new mathematical modelling of in vivo pharmacokinetic and pharmacodynamic processes and quantitatively assessed experiments.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available